We use digital human cells
to understand diseases

Our AI-driven biosimulation platform provides unprecedented decision analytics to de-risk drug discovery

Request a Demo
Cloud Platform

OUR LATEST MECHANISTIC ODE MODEL FEATURES

Genes
0 K⇧
Molecular Species (Proteins & Metabolites)
0 K⇧
Gene-Associated Chemical Reactions
0 K⇧

THE COMPANY

Netabolics Predictive Biosimulation

Netabolics is an award-winning AI-driven biotech startup based in Rome, Italy. The company works to bring disruptive innovations in the pharmaceutical R&D processes. Our team includes life scientists and software engineers working collaboratively to produce the best genome-scale simulation of cellular biology for in silico drug target selection.

Our discovery platform predicts the many thousands biological changes occurring inside any cell type in response to pharmacological, genetic and environmental factors — in seconds. Predictions do not have to be perfect, but they need to inform decision-making in drug discovery, because quicker Go/No-Go decisions accelerate the progress towards safe and effective medicines for patients.

Mauro DiNuzzo, Founder & CEO
Linkedin
At Netabolics, we envision a future where drug discovery is transformed through the power of AI and biosimulation. Imagine a world where you can simply specify the desired outcome, such as a healthy cellular phenotype, and let our technology identify the most promising biological target, or combination thereof, for advancing your drug discovery pipeline.

Our mission is to accelerate the development of new medicines that make an impact on people.

We have an international network of academic, industrial, and technological partners,  collaborating research laboratories, and customers that trust our technology.
We constantly seek mission-aligned partners to advance our discovery platform.
Partner With Us

THE TECHNOLOGY

Where AI Meets Biosimulation

Our  patented   technology couples ordinary differential equations (ODEs) with deep reinforcement learning (DRL) overlaid onto first principles of physics and biology to automate networks/systems biology and pharmacology model simulations and empower drug discovery project teams to identify and validate biological targets of diseases and disease biomarkers.

By leveraging artificial intelligence, publicly available knowledge base, and internal databases, our proprietary algorithms create mechanistic dynamical systems starting from digital reconstructions of human cells for simulating cellular biology and predicting the effect of new drugs.

What is slowing down your R&D process in a typical use case scenario.

You have multiomics (e.g., transcriptomics RNAseq) data from healthy and diseased cells.

You get a ranked list of differentially expressed genes/proteins and you can prioritize few of them for validation and further development.

You don’t know if each of those targets is disease-associated or disease-modifying (disease understanding).
You don’t know how diseased cells respond to perturbations of each of those targets (efficacy).
You don’t know how healthy cells respond to perturbations of each of those targets (toxicity).
You don’t know how many other targets relevant to disease with normal expression pattern you have missed!

What is our approach to in silico drug target selection using AI and biosimulation.

We believe in simplifying the drug discovery process. Instead of navigating through complex pathways and countless potential biological targets, you can now focus on your desired outcome. Whether it’s targeting specific cellular functions or achieving a particular therapeutic effect, Netabolics empowers you to set the goal, and the platform will handle the rest.

Every project is unique, and so are your goals. Netabolics tailors its simulations to your specific requirements, ensuring a personalized approach to drug discovery. Whether you are a pharmaceutical company, research institution, or a biotech startup, our platform adapts to your needs, providing a customized solution for your projects.
Our platform utilizes state-of-the-art biosimulation and AI/ML models to simulate and analyze biological networks. By leveraging advanced deep reinforcememt learning (DRL) algorithms, Netabolics identifies efficacy and toxicity biomarkers as well as the optimal biological targets that align with your defined outcome (e.g., as mono- or combination therapy). This accelerates the drug discovery process, saving you time and resources.

THE PLATFORM

Drug Target Selection in the Cloud

Our platform integrates the predictive power of AI/ML with the explainable and deterministic nature of ordinary differential equation (ODE)-based biosimulation. Applications include what-if scenario analysis to validate known biological targets, and target deconvolution analysis to discover novel biological targets.

We help identify and validate the biological targets of disease, predicts the biological effects of new drugs and optimize their efficacy and toxicity profile, which translates in substantial time and cost savings.

Cloud Platform

Here we show our predictive analytics on a model system of pan-cancer metabolism.

Our proprietary biosimulation algorithms are rooted in biochemistry and are incorporated in a suite of powerful computational tools based on AI/ML that ensure full compliance with non-equilibrium thermodynamics across the entire modeling pipeline.

Mauro DiNuzzo. How artificial intelligence enables modeling and simulation of biological networks to accelerate drug discovery. Frontiers in Drug Discovery, Section In silico Methods and Artificial Intelligence for Drug Discovery, Volume 2 (2022). https://doi.org/10.3389/fddsv.2022.1019706

Mauro DiNuzzo, Alessandro Scandurra, Marco Salvatore. Biosimulation-based target deconvolution of cancer metabolism. RExPO24 Conference, 3 (2024). https://doi.org/10.58647/REXPO.24000057.v1
Download White Paper

PIPELINE

Combinational drug discovery & repurposing

The following table provides an overview of our early-stage development programs.

THERAPEUTIC AREA

TARGET

DISCOVERY

OPTIMIZATION

IND-ENABLING

CLINICAL

Oncology

Multiple Targets

Our pipeline is powered by in silico research and development capabilities. We are focused on discovering new combinations of repurposed drugs for oncology. We actively explore partnerships for co-development.

Not sure about our discovery platform? Don't trust us. Request a demo.

Ready to revolutionize your drug discovery pipeline? Contact Netabolics today to join the waitlist and explore how our AI-powered simulations can propel your projects forward. 

* Required fields

Netabolics received funding from the European Regional Development Fund Pre-Seed Regione Lazio POR-FESR 2014-2020. The aim of the Pre-Seed grant (Prot. n. A0122-2020-34411 - 10/03/2020) is to support the development of the proprietary cloud platform of the company (as academic spin-off) and the consolidation of the business idea to make it ready for the market.

Netabolics received funding from the European Regional Development Fund Voucher Internazionalizzazione Regione Lazio POR-FESR 2021-2027. The aim of the project (Prot. n. A0655-2023-080608 - 10/12/2023) is to support the participation of the company to the following international events: BioTechX Europe (Basel, Switzerland, 9-10 October 2024), Festival of Biologics (Basel, Switzerland, 15-17 October 2024), Welfair (Rome, Italy, 5-7 November 2024), AI-Driven Drug Discovery Summit (Boston, USA, 12-14 November 2024).

Blocco_Fondi_europei_positivo_hires

Netabolics is a proud associate member of the   LazioInnova network.

Netabolics is a deep tech based biotechnology company. Our mission is to leverage genome-scale biosimulation and AI/ML to understand the biology of diseases and discover novel combination therapies.

COOKIE POLICY  PRIVACY POLICY  TERMS OF USE

Circonvallazione Ostiense 229
00154 Rome, Italy

Youtube Linkedin

Netabolics and Netabolics logo are registered trademarks of Netabolics SRL. Copyright © 2020-2024 Netabolics. All rights reserved.